



**FOR IMMEDIATE RELEASE**

## **CLC bio provides bioinformatics solution for vaccine target development to ACE BioSciences**

Odense & Aarhus, Denmark -- December 18, 2007 -- ACE BioSciences, an emerging pharmaceutical company focused on developing novel protein-based vaccines and antibodies to address infectious diseases, and CLC bio, the world's leading bioinformatics solutions provider, today announced a collaborative bioinformatics agreement.

Dr. Ingelise Saunders, Chief Executive Officer at ACE BioSciences said, 'At ACE BioSciences we place considerable emphasis on selecting partners based on their scientific know-how - and in that regard we recognize CLC bio as the leading company within bioinformatics, with a global reputation and internationally renowned experts. We see this collaboration as a significant opportunity to augment and expand our bioinformatics platform to increase efficiency, enhance our analyses, and accelerate our research.'

Dr. Jannick D. Bendtsen, project manager and Senior Scientific Officer at CLC bio commented, 'We are looking forward to this collaboration, which is scientifically interesting and challenging. The implementation of our customized software will streamline and fast-track analysis and further increase statistical confidence in the selection of novel candidates for inclusion in the ACE BioSciences' development portfolio. Implementation of automated target validation protocols will increase efficiency and the rate of data throughput, improve quality assurance and enhance data security.'

Under the terms of the agreement, CLC bio will upgrade and expand ACE BioSciences' existing bioinformatics platform to ensure the company is taking advantage of the most up-to-date, relevant, and innovative software, including state-of-the-art protein vaccine target characterization. In addition, CLC bio will provide greater integration and cross-referencing capabilities, securing for ACE BioSciences the ability to apply more extensive statistical analyses to its databases and laboratory information. CLC bio's customized solution will strengthen ACE BioSciences' ability to compare, rank, and prioritize potential vaccine targets.

The solution provided to ACE BioSciences consists of a number of CLC workbenches for DNA, RNA, and protein sequence analysis, supplemented with customized bioinformatics modules that are proprietary for ACE BioSciences.

Read more about CLC bio's customized software solutions on [www.clcbioconsulting.com](http://www.clcbioconsulting.com)



## About ACE BioSciences

ACE BioSciences is an emerging pharmaceutical company focused on developing novel protein-based vaccines and antibodies to address infectious diseases. It has unique expertise in the extraction and analysis of the cell surface proteins used by pathogens (eg bacteria, viruses and fungi) to interact with and infect human host cells.

The company's lead product, ACE393, is an injectable vaccine that is on track to become the world's first commercial vaccine for Travellers' Diarrhoea caused by *Campylobacter* infection, having successfully completed Phase I clinical trials in March 2007.

*Campylobacter* is one of the greatest causes of gastroenteritis in the developed world as well as a significant contributor to travellers' diarrhoea. The annual global commercial market for a *Campylobacter* vaccine is estimated to be worth € 350 million.

ACE BioSciences aims to develop a portfolio of products independently and in collaboration with other companies and as part of that strategy the company signed a collaborative development agreement with the US Naval Medical Research Center (NMRC) to progress ACE393 through Phase II clinical trials. In addition to ACE393, the company is working on ACE537, an oral, Phase I, Enterotoxigenic *E Coli* (ETEC) vaccine which has the potential to be the first to market in the US and EU and which combats the single biggest cause of travelers diarrhoea. It is also working on a vaccine for *Streptococcus pneumoniae*, the bacterium responsible for Pneumococcal disease. The market for a *Streptococcus* product would be multibillion and ACE BioSciences aims to partner the project.

## About CLC bio

CLC bio is the world's leading full-service bioinformatics solution provider, solely focusing on the development of bioinformatics: software, hardware, data analysis, and custom-designed bioinformatics algorithms. CLC bio is an Apple solution provider and value added reseller.

CLC bio's mission is to be among the most innovative bioinformatics companies in the 21<sup>st</sup> century. This is realized through:

- Development of bioinformatics software and hardware based on the latest scientific findings
- User-friendly, integrated and intuitive cross-platform software solutions
- Continuous focus on customer needs and superior customer service
- Frequent product updates including the latest IT technologies and bioinformatics algorithms
- A flexible IT architecture, enabling customers to buy or develop individualized solutions at a reasonable price



## Contact

For further information, please contact:

Dr. Ingelise Saunders, CEO  
ACE BioSciences A/S  
Unsbjergvej 2a  
DK-5220 Odense SØ  
Denmark  
Phone: +45 6565 2121  
E-mail: [mail@acebiosciences.com](mailto:mail@acebiosciences.com)  
Website: [www.acebiosciences.com](http://www.acebiosciences.com)

Thomas Knudsen, CEO  
CLC bio  
Gustav Wieds Vej 10  
8000 Aarhus C  
Denmark  
Phone: +45 70 22 55 09  
E-mail: [info@clcbio.com](mailto:info@clcbio.com)  
Website: [www.clcbio.com](http://www.clcbio.com)